SEC Form 4 · accession 0001209191-15-034053

KalVista Pharmaceuticals, Inc. · KALV

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

10% Owner

10% Owner

10% Owner

Period of report

Apr 14, 2015

Accepted (ET)

Apr 14, 2015 · 5:24 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001348911

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Apr 14, 2015	C	727,590	—	A	727,590	I	See Footnote
Common Stock^F1,F2	Apr 14, 2015	C	1,981,124	—	A	2,708,714	I	See Footnote
Common Stock^F3,F2	Apr 14, 2015	C	424,346	—	A	3,133,060	I	See Footnote
Common Stock^F4,F2	Apr 14, 2015	C	332,990	—	A	3,466,050	I	See Footnote
Common Stock^F2	Apr 14, 2015	P	877,500	$5.00	A	4,343,550	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A Convertible Preferred Stock^F1,F2	—	Apr 14, 2015	C	727,590	D	—	—	Common Stock	727,590	I
Series B Convertible Preferred Stock^F1,F2	—	Apr 14, 2015	C	1,981,124	D	—	—	Common Stock	1,981,124	I
Convertible Promissory Note^F3,F2	—	Apr 14, 2015	C	424,346	D	—	—	Common Stock	424,346	I
Convertible Promissory Note^F4,F2	—	Apr 14, 2015	C	332,990	D	—	—	Common Stock	332,990	I

F1Upon the closing of the Issuer's initial public offering, each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into Common Stock on a one for one basis without payment or further consideration, and has no expiration date.
F2These securities are held by ACP IV, L.P ("ACP IV"). Daniel S. Janney and Guy P. Nohra are directors of ACMP IV, LLC, the general partner of ACP IV and disclaim beneficial ownership of these securities except to the extent of any pecuniary interest therein.
F3The Convertible Promissory Note is convertible into the number of shares of the Issuer's Common Stock equal to the quotient obtained by dividing the entire principal amount and 184 days of accrued interest on the Convertible Promissory Note by 80% of the initial public offering price of $5.00 per share of the Issuer's Common Stock, automatically upon the closing of the Issuer's initial public offering, and has no expiration date.
F4The Convertible Promissory Note is convertible into the number of shares of the Issuer's Common Stock equal to the quotient obtained by dividing the entire principal amount and 41 days of accrued interest on the Convertible Promissory Note by 80% of the initial public offering price of $5.00 per share of the Issuer's Common Stock, automatically upon the closing of the Issuer's initial public offering, and has no expiration date.